The pharmaceutical industry's use of gifts and educational events to influence prescription practices: Ethical dilemmas and implications for psychologists

Professional Psychology: Research and Practice

Volumn 35, Issue 4, 2004, Pages 329-335

  Reist, David ^a,b   VandeCreek, Leon ^a  

^a WRIGHT STATE UNIVERSITY   (United States)

^b Wright State University ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 3543046750     PISSN: 07357028     EISSN: None     Source Type: Journal    
DOI: 10.1037/0735-7028.35.4.329     Document Type: Review

References (51)

1. American Psychological Association. (2002). Ethical Principles of Psychologists and Code of Conduct. American Psychologist, 57, 1060-1073.
2. American Psychological Association. (2003). Ratecard. Retrieved April 14, 2003, from http.www.apa.org/ads/ratecard.other.html
3. Antonuccio, D., & Danton, W. (2003). Prescription privileges 102: Biting the hand that's trying to feed you. Clinical Psychologist, 56(2), 17-18.
4. Bower, A., & Burkett, G. (1987). Family physicians and generic drugs. Journal of Family Practice, 24, 612-616.
5. Bowman, M., & Pearls, D. (1988). Changes in drug prescribing patterns related to commercial company funding of continuing education. Journal of Continuing Education in Health Professions, 8, 13-20.
6. Buelow, G., & Chafetz, M. (1996). Proposed ethical practice guidelines for clinical pharmacopsychology: Sharpening a new focus in psychology. Professional Psychology: Research and Practice, 27, 53-58.
7. Caudill, T., Johnson, M., Rich, E., & McKinney, W. (1996). Physicians, pharmaceutical sales representatives and the cost of prescribing. Archives of Family Medicine, 5, 201-206.
8. Council on Ethics and Judicial Affairs, American Medical Association. (1991). Gifts to physicians from industry. Journal of the American Medical Association, 265, 501.
9. DeAngelis, T. (2003). What industry funding means for APA. Monitor on Psychology, 34(7), 29.
10. DeLeon, P., Bennett, B., & Bricklin, P. (1997). Professional Psychology: Research and Practice, 28, 518-525.
11. Food and Drug Administration. (2002). Guidance for industry: Prescription drug marketing act regulations for the donation of prescription drug samples to free clinics. Retrieved August 22, 2003, from http://www.fda.gov/cder/guidance/ index.htm
12. Fortune 500: How the industries stack up. (2002). Fortune, 145(8), F-24.
13. Gibbons, R., Landry, F., Blouch, D., Jones, D., Williams, F., Lucey, C., & Kroenke, K. (1998). A comparison of physicians' and patients' attitudes toward pharmaceutical industry gifts. Journal of General Internal Medicine, 13, 213-215.
14. Griffith, D. (1999). Reasons for not seeing drug representatives. British Medical Journal, 319, 69-70.
15. Haayer, F. (1982). Rational prescribing and sources of information. Social Science Medicine, 16, 2017-2023.
16. Healy, D. (2003). Psychopharmacology 102 (. . .What they neglected to mention in psychopharmacology 101). Clinical Psychologist, 56(2), 10-17.
17. Holmer, A. (2002, November). The case for innovation: The role of intellectual property protection. Paper presented at the Economist's Second Annual Pharmaceuticals Roundtable, Philadelphia, PA.
18. Hopper, J., Speece, M., & Musial, J. (1997). Effects of an educational intervention on residents' knowledge and attitudes toward interactions with pharmaceutical representatives. Journal of General Internal Medicine, 12, 639-642.
19. Kahneman, D., & Tversky, A. (1973). Availability: A heuristic for judging frequency and probability. Cognitive Psychology, 5, 207-232.
20. Katz, D., Caplan, A. L., & Merz, J. F. (2003). All gifts large and small: Toward an understanding of the ethics of pharmaceutical industry gift giving. American Journal of Bioethics, 3(3), 39-46.
21. Kirsch, I. (2003). Prescribing privileges for psychologists: A cost benefit comment. Clinical Psychologist, 56(2), 18-20.
22. Koocher, G., & Keith-Spiegel, P. (1998). Ethics in psychology: Professional standards and cases (2nd ed.). New York: Oxford University Press.
23. Kowalczyk, L. (2003, May 25). Drug companies' secret reports outrage doctors, Boston Globe, p. A1.
24. Lassetter, J., & Warnick, M. (2003). Medical errors, drug-related problems, and medication errors: A literature review on quality of care and cost issues. Journal of Nursing Care Quality, 18(3), 175-181.
25. Levant, R., & Sammons, M. (2003). What history 103 can teach us about psychopharmacology 102: A reply to Healy. Clinical Psychologist, 56(2), 21-22.
26. Lexchin, J. (1989). Doctors and detailers: Therapeutic education or pharmaceutical promotion? International Journal of Health Services, 19, 663-679.
27. Lexchin, J. (1993). Interactions between physicians and the pharmaceutical industry. Canadian Medical Association Journal, 149, 1401-1407.
28. Lexchin, J. (1997). What information do physicians receive from pharmaceutical representatives? Canadian Family Physician, 43, 941-945.
29. Mainous, A., Hueston, W., & Rich, E. (1995). Patient perceptions of physician acceptance of gifts from the pharmaceutical industry. Archives of Family Medicine, 4, 335-339.
30. Masters, B. A. (2003, May 31). Drug company unit may face indictment. Washington Post, p. El.
31. Mavissakalian, M. (2003). Comments on Psychopharmacology 102. Clinical Psychologist, 56(2), 23-24.
32. McCormick, B., Tomlinson, G., Brill-Edwards, P., & Detsky, A. (2001). Effect of restricting contact between pharmaceutical company representatives and internal medicine residents on post-training attitudes and behavior.Journal of the American Medical Association, 286, 1994-1999.
33. Morelli, D., & Koenigsberg, M. (1992). Sample medication dispensing in a residency practice. Journal of Family Practice, 34, 42-48.
34. National Institute for Health Care Management. (2002). Changing patterns of pharmaceutical innovation. Retrieved August 22, 2003, from http://www.nihcm.org
35. Orlowski, J., & Wateska, L. (1992). The effects of pharmaceutical firm enticements on physician prescribing patterns. Chest, 102, 270-273.
36. Peay, M., & Peay, R. (1988). The role of commercial sources in the adoption of a new drug. Social Science Medicine, 26, 1183-1189.
37. Pharmaceutical Research and Manufacturers of America. (2002). Back-grounder of new code on interactions with healthcare professionals. Retrieved February 13, 2003, from http://www.pharma.org/publications/quickfacts/ 19.04.2002.388.cfm
38. Preston, J., & Ebert, B. (1999, October). Psychologists' role in the discussion of psychotropic medication with clients: Legal and ethical considerations. California Psychologist, pp. 32, 34.
39. Rosenthal, M., Berndt, E., Donohue, J., Frank, R., & Epstein, A. (2002). Promotion of prescription drugs to consumers. New England Journal of Medicine, 346, 498-505.
40. Sammons, M., Paige, R., & Levant, R. (2003). Prescribing psychologists: The future. In M. Sammons, R. Levant, & R. Paige (Eds.), Prescriptive authority for psychologists: A history and guide (pp. 191-212). Washington, DC: American Psychological Association.
41. Shaughnessy, A., Slawson, D., & Bennett, J. (1995). Teaching information mastery: Evaluating information provided by pharmaceutical representatives. Family Medicine, 27, 581-585.
42. Spingarn, R., Berlin, J., & Strom, B. (1996). When pharmaceutical manufacturers' employees present grand rounds, what do residents remember? Academic Medicine, 71, 86-88.
43. Thomas, J. (2003). Keeping drug companies at arms length is puzzle. National Psychologist, 12(2), 1.
44. VandenBos, G., & Williams, S. (2000). Is psychologists' involvement in the prescribing of psychotropic medication really a new activity? Professional Psychology: Research and Practice, 31, 615-618.
45. Vedantam, S. (2002, May 26). Industry role in medical meeting decried. Washington Post, p. A10.
46. Wazana, A. (2000). Physicians and the pharmaceutical industry; is a gift ever just a gift? Journal of the American Medical Association, 283, 373-379.
47. Wilkes, M., Bell, R., & Kravitz, R. (2000). Direct-to-oonsumer prescription drug advertising: Trends, impact, and implications. Health Affairs, 19, 110-128.
48. Wilkes, M., & Hoffman, J. (2001). An innovative approach to educating medical students about pharmaceutical promotion. Academic Medicine, 76, 1271-1277.
49. Wright, R. (1998, November). Face, dissonance, and drug lunches. Paper presented at the meeting of the Health Communication Division of the National Communication Association, New York.
50. Zeuger, A. (1999, January 11). Fever pitch: Getting doctors to prescribe is big business. New York Times, p. 1.
51. Ziegler, M., Lew, P., & Singer, B. (1995). The accuracy of drug information from pharmaceutical sales representatives. Journal of the American Medical Association, 273, 1296-1298.